Clin Exp Vaccine Res.  2015 Jan;4(1):54-58. 10.7774/cevr.2015.4.1.54.

Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease

• Lim YT

• KMID: 2049107
• DOI: http://doi.org/10.7774/cevr.2015.4.1.54

Abstract

Adjuvants can be defined as pharmacological and immunological components that are able to modify and/or enhance antigen-specific immune responses. Based on the interdisciplinary research between immunology and material science/engineering, various vaccine adjuvant materials have been developed. By rational design and engineering of antigen or adjuvant materials, immune-modulatory vaccine systems generated to activate immune system. Here, we review the current progress of bioengineered prophylactic and/or therapeutic vaccine adjuvant for cancer and/or infectious disease, and discuss the prospect of future vaccine adjuvant materials.

Keyword

Immunological adjuvants; Immunotherapy; Immunomodulation

MeSH Terms

Adjuvants, Immunologic
Allergy and Immunology
Communicable Diseases*
Immune System
Immunomodulation
Immunotherapy*
Adjuvants, Immunologic

Reference

1. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009; 462:449–460.

2. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19:1597–1608.

3. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82:488–496.

4. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009; 30:23–32.

5. Griffiths KL, Khader SA. Novel vaccine approaches for protection against intracellular pathogens. Curr Opin Immunol. 2014; 28:58–63.

6. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future perspectives. Int J Pharm. 2013; 440:27–38.

7. Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines. 2012; 11:995–1007.

8. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. 2013; 12:978–990.

9. Moon JJ, Huang B, Irvine DJ. Engineering nano- and microparticles to tune immunity. Adv Mater. 2012; 24:3724–3746.

10. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol. 2010; 22:411–416.

11. Riese P, Schulze K, Ebensen T, Prochnow B, Guzman CA. Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem. 2013; 13:2562–2580.

12. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009; 106:7962–7967.

13. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011; 3:85ra48.

14. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007; 13:552–559.

15. Wiley SR, Raman VS, Desbien A, et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med. 2011; 3:93ra69.

16. Draper E, Bissett SL, Howell-Jones R, et al. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) human papillomavirus vaccines in 12-15 year old girls. PLoS One. 2013; 8:e61825.

17. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006; 25:373–381.

18. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006; 25:349–360.

19. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5:987–995.

20. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002; 20:197–216.

21. Sansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat Immunol. 2006; 7:1237–1242.

22. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124:783–801.

23. Chang YC, Madkan V, Cook-Norris R, Sra K, Tyring S. Current and potential uses of imiquimod. South Med J. 2005; 98:914–920.

24. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176:4894–4901.

25. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol. 2005; 77:378–387.

26. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004; 4:249–258.

27. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27:687–690.

28. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005; 11:4 Suppl. S45–S53.

29. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6:148–158.